论文部分内容阅读
目的 :探讨骨髓增生异常综合征伴原始细胞增多转变型 (MDS- RAEBT)与急性单核细胞白血病 (AML- M5型 )临床疗效的区别及其与细胞凋亡的关系。方法 :观察以 DAE或 HAE为基本方案化疗的 MDS- RAEBT和 AML- M5两组患者的临床疗效。用常规方法提取 2 2例 MDS- RAEBT和 2 8例 AML- M5初治患者的单个核细胞 ,并分别用 EL ISA方法 FACS方法检测两组患者血浆中的可溶性 FAS(soluble isoform s of the fas,s FAS)和细胞凋亡相对百分比。结果 :MDS- RAEBT组血浆中的 s FAS水平高于 AML- M5组 ,而细胞凋亡相对百分比和 2个疗程的完全缓解率均低于 AML- M5组 ,两组之间各指标比较差异有显著性 (P<0 .0 5 )。结论 :MDS- RAEBT与 AML- M5两者之间有明显的临床疗效差别 ,可能与 s FAS抑制细胞凋亡有关。
Objective: To investigate the difference between the clinical efficacy of myelodysplastic syndrome (MDS-RAEBT) and acute monocytic leukemia (AML-M5) and its relationship with apoptosis. Methods: The clinical efficacy of MDS-RAEBT and AML-M5 patients treated with DAE or HAE as the basic regimen was observed. Mononuclear cells of 22 patients with MDS-RAEBT and 28 patients with untreated AML-M5 were extracted by routine methods and their plasma soluble FAS (soluble isoform s of the fas, s FAS) and relative percentage of apoptosis. Results: The plasma levels of sFAS in MDS-RAEBT group were higher than those in AML-M5 group, and the relative percentages of apoptosis and complete remission rate in 2 courses were lower than those in AML-M5 group Significance (P <0.05). Conclusion: There is a significant clinical difference between MDS-RAEBT and AML-M5, which may be related to the inhibition of apoptosis by s FAS.